Nektar Therapeutics hits downward sloped trend line and gets bearish signal
Nektar Therapeutics (Nasdaq: NKTR) is a biopharmaceutical company that drugs for cancer, autoimmune diseases, and chronic pain. The company’s fundamental indicators are all over the place, but the stock has been trending lower since September.
If we connect the closing high from September with intraday high from February, it creates a trend line that the stock just hit in the last few days. We see the trend line on the daily chart, but what we don’t see on the daily chart is that the high from September was in close proximity to a gap in the chart from 2018. That gap was in the $70 area.
We also see that the daily stochastic readings and the 10-day RSI had reached overbought levels in the last few days before they turned lower on Friday and Monday.
The Tickeron AI Trend Prediction tool generated a bearish signal on the stock on May 10. The signal only showed a confidence level of 59%, but the past signals on Nektar have been successful 90% of the time. This prediction calls for a 2.5% decline in the next week.
I mentioned earlier that Nektar’s fundamentals are over the place. Earnings have been flat over the last three years and fell by 13% in the most recent quarterly report. Sales have increased by a rate of 128% per year over the last three years, but fell by 26% in the most recent quarter. The ROE is at 75.5% and the profit margin is at 57.2%. Both of those figures are well above average.
NKTR's Stochastic Oscillator remains in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NKTR moved out of overbought territory on February 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for NKTR turned negative on March 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NKTR broke above its upper Bollinger Band on February 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on March 10, 2026. You may want to consider a long position or call options on NKTR as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
NKTR moved above its 50-day moving average on February 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NKTR crossed bullishly above the 50-day moving average on February 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTR advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 148 cases where NKTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NKTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.096) is normal, around the industry mean (30.264). P/E Ratio (0.000) is within average values for comparable stocks, (40.876). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.802). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (17.889) is also within normal values, averaging (313.223).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of inhalation drug delivery systems
Industry Biotechnology
Advertisement